Optimal Proteinuria Target for Renoprotection in Patients with IgA Nephropathy
نویسندگان
چکیده
منابع مشابه
Optimal Proteinuria Target for Renoprotection in Patients with IgA Nephropathy
BACKGROUND Proteinuria is a target for renoprotection in kidney diseases. However, optimal level of proteinuria reduction in IgA nephropathy (IgAN) is unknown. METHODS We conducted a retrospective observational study in 500 patients with biopsy-proven IgAN. Time-averaged proteinuria (TA-P) was calculated as the mean of every 6 month period of measurements of spot urine protein-to-creatinine r...
متن کاملSeasonal proteinuria changes in IgA nephropathy patients after proteinuria remission
BACKGROUND Proteinuria is a powerful prognostic factor for end-stage renal disease in IgA nephropathy (IgAN) patients. However, it is not known whether proteinuria exacerbations are related to seasonal changes. METHODS We retrospectively enrolled consecutive patients diagnosed with IgAN by kidney biopsy at our hospital between 2002 and 2014. Proteinuria remission was defined as urinary protei...
متن کاملPrednisolone Co-Administered with Losartan Confers Renoprotection in Patients with IgA Nephropathy
BACKGROUND Treatment options for progressive IgA nephropathy are limited. METHODS We performed a small, randomized controlled trial to evaluate the effects of prednisolone (PSL, 30 mg/dL, gradually tapered to 5 mg/dL over two years) plus 50 mg/day of losartan (LST, an angiotensin II receptor blocker) or PSL alone on IgA nephropathy. We separated 38 patients (age, 33 +/- 11 years; creatinine c...
متن کاملPatients with IgA Nephropathy
The actual state of IgA nephropathy in Japan was surveyed throughout the nation by a questionnaire. Five hundred patients were collected from 26 departments of pediatrics and 2,1 75 from 27 internal medicine. IgA nephropathy accounted for 19.2% of the children and 30.0% of the adults among primary glomerular diseases. Most of the patients, regardless children and adults, were detected by chance...
متن کاملOptimal dose of losartan for renoprotection in diabetic nephropathy.
BACKGROUND Angiotensin II subtype-1 receptor antagonists represent a valuable new class of drugs in the treatment of diabetic nephropathy. The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy. METHODS Fifty consecutive hypertensive type 1 diabetic patients with diabetic nephropathy received increasing doses o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLoS ONE
سال: 2014
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0101935